Literature DB >> 1119764

Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.

H J Cohen, L S Lessin, J Hallal, P Burkholder.   

Abstract

A patient with primary amyloidosis with evidence for a plasma cell dyscrasia but no abnormal immunoglobulin components had nephrotic syndrome with severe renal impairment. Kidney and bone marrow had extensive amyloid infiltration. She was treated with penicillamine, malphalan, prednisone, and fluoxymesterone; through 6 months renal function gradually improved; urine protein excretion dropped dramatically, serum albumin rose; liver size decreased; the bone marrow returned towards normal. During the next 4 1/2 years melphalan, prednisone, and fluoxymesterone treatment was continued with further improvement in renal function to normal levels. The morphologic characteristics and cellular relations of amyloid fibrils in the bone marrow were studied before, during, and after successful chemotherapy; the findings are evidence for a dual role for the reticuloendothelial cell in the formation and destruction of primary amyloidosis. This patient's response suggests that a multi-agent chemotherapy approach should be further studied.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1119764     DOI: 10.7326/0003-4819-82-4-466

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  14 in total

1.  Aberrant immunoglobulin synthesis in light chain amyloidosis. Free light chain and light chain fragment production by human bone marrow cells in short-term tissue culture.

Authors:  J Buxbaum
Journal:  J Clin Invest       Date:  1986-09       Impact factor: 14.808

2.  Primary amyloidosis, paraproteinaemia and neuropathy.

Authors:  B M Kaufman
Journal:  Proc R Soc Med       Date:  1976-09

3.  Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.

Authors:  M A Gertz; M Q Lacy; J A Lust; P R Greipp; T E Witzig; R A Kyle
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

4.  The kidney in myeloma.

Authors:  T J Hamblin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

5.  Colchicine therapy for nephrotic syndrome due to familial Mediterranean fever.

Authors:  G Skrinskas; R A Bear; A Magil; K Y Lee
Journal:  Can Med Assoc J       Date:  1977-12-17       Impact factor: 8.262

6.  Renal amyloidosis.

Authors:  N F Jones
Journal:  J Clin Pathol       Date:  1981-11       Impact factor: 3.411

7.  [Primary amyloidosis with nephrotic syndrome: 5 year follow-up under polychemotherapy. A case report (author's transl)].

Authors:  B Emmerich; A Kircher; U Fink; L Schmid; J Rastetter
Journal:  Klin Wochenschr       Date:  1980-11-03

Review 8.  Dubious effect of dimethylsulphoxide (DMSO) therapy on amyloid deposits and amyloidosis.

Authors:  E Gruys; R J Sijens; W J Biewenga
Journal:  Vet Res Commun       Date:  1981-09       Impact factor: 2.459

9.  Amyloid myopathy and myeloma: response to treatment.

Authors:  R A Sheehan-Dare; A V Simmons
Journal:  Postgrad Med J       Date:  1987-02       Impact factor: 2.401

10.  Pattern of renal amyloidosis in Indian patients.

Authors:  K S Chugh; B N Datta; P C Singhal; S K Jain; V Sakhuja; S C Dash
Journal:  Postgrad Med J       Date:  1981-01       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.